secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2022-03-16T23:59:59+00:00
Accession:  0001564590-22-010644
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics appoints Utpal Koppikar to board; Elena Prokupets resigns
-------------------------------------------------------------------------

- Utpal Koppikar elected as director effective March 16, 2022; will chair Audit Committee and serve on Organization, Leadership and Compensation Committee.
- Koppikar is CFO of Atara Biotherapeutics; previously VP at Gilead Sciences and executive director at Amgen.
- Granted stock options for 41,200 shares vesting over three years with annual cliff.
- Elena Prokupets resigned March 10, 2022; resignation not due to any disagreement with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000156459022010644/0001564590-22-010644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000156459022010644/cccc-8k_20220310.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-010644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer